FOSTER CITY, Calif. & SOUTH SAN FRANCISCO, Calif., December 22, 2025--Gilead Sciences, Inc. (Nasdaq: GILD) and Assembly ...

Scientists used a clinical-grade gum in experiments to "substantially" lower viral loads of two herpes simplex viruses and ...

Researchers have found in a new study published in JAMA that valacyclovir showed no efficacy and was associated with ...

Gilead licensed Assembly Bio's long-acting HSV drugs after Phase 1b data showed antiviral activity and weekly oral dosing potential.

Gilead exercises its option to license ASMB's HSV programs for developing long-acting candidates, ABI-1179 & ABI-5366, for recurrent genital herpes.

Nine-ingredient formula featuring L-lysine, elderberry, and botanical extracts positions product among growing category of ...

Two years after Gilead Sciences secured the first option on Assembly Biosciences’ entire pipeline, the pharma has decided to ...

New York State Psychiatric Institute and Columbia University Medical Center investigators, with co-authors across additional US centers, report greater cognitive worsening at 78 weeks with ...

Infections accelerate aging by damaging cells and organs. Preventing them with vaccines, hand hygiene, masks, and clean air ...

A sharp rise in rare and fatal brain infections—from Kerala’s Naegleria fowleri cases to Japanese encephalitis across 11 ...

A media marketing manager has settled her lawsuit against a former partner she accused of infecting her with an incurable and life-altering herpes virus after promising he was disease-free and failing ...